Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1

Xian Li,Mengxin Xu,Jingyi Yang,Li Zhou,Lin Liu,Min Li,Shasha Wang,Mei-Qin Liu,Zhixiang Huang,Zhen Zhang,Shuning Liu,Yunqi Hu,Haofeng Lin,Bowen Liu,Ying Sun,Qingguo Wu,Zheng-Li Shi,Ke Lan,Yu Chen,Huimin Yan,Yao-Qing Chen
DOI: https://doi.org/10.1038/s41392-024-01822-3
IF: 39.3
2024-04-27
Signal Transduction and Targeted Therapy
Abstract:Developing a mucosal vaccine against SARS-CoV-2 is critical for combatting the epidemic. Here, we investigated long-term immune responses and protection against SARS-CoV-2 for the intranasal vaccination of a triple receptor-binding domain (RBD) scaffold protein (3R-NC) adjuvanted with a flagellin protein (KFD) ( 3R-NC + KFDi.n ). In mice, the vaccination elicited RBD-specific broad-neutralizing antibody responses in both serum and mucosal sites sustained at high level over a year. This long-lasting humoral immunity was correlated with the presence of long-lived RBD-specific IgG- and IgA-producing plasma cells, alongside the Th17 and Tfh17-biased T-cell responses driven by the KFD adjuvant. Based upon these preclinical findings, an open labeled clinical trial was conducted in individuals who had been primed with the inactivated SARS-CoV-2 (IAV) vaccine. With a favorable safety profile, the 3R-NC + KFDi.n boost elicited enduring broad-neutralizing IgG in plasma and IgA in salivary secretions. To meet the challenge of frequently emerged variants, we further designed an updated triple-RBD scaffold protein with mutated RBD combinations, which can induce adaptable antibody responses to neutralize the newly emerging variants, including JN.1. Our findings highlight the potential of the KFD-adjuvanted triple-RBD scaffold protein is a promising prototype for the development of a mucosal vaccine against SARS-CoV-2 infection.
biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to develop a mucosal vaccine against SARS - CoV - 2 and its variants to provide long - term protection. Specifically, the research aims to induce a long - lasting broad - spectrum neutralizing antibody response by intranasal vaccination with a triple receptor - binding domain (RBD) scaffold protein (3R - NC) and flagellin (KFD) adjuvant, thereby combating SARS - CoV - 2 infection, especially emerging variants such as JN.1. ### Main research objectives: 1. **Induce a long - lasting immune response**: The research aims to induce a long - term RBD - specific neutralizing antibody response by intranasal vaccination with the 3R - NC + KFD vaccine, and these antibodies can maintain high levels in both serum and mucosal sites. 2. **Establish effective mucosal immunity**: The research explored whether the 3R - NC + KFD vaccine can establish effective mucosal immunity in the upper respiratory tract, because initial infection and virus replication mainly occur in nasal ciliated cells. 3. **Deal with frequently emerging variants**: The research designed an updated triple RBD scaffold protein, containing a mutated RBD combination, to induce an adaptive antibody response and neutralize emerging variants such as JN.1. ### Research background: - Although current SARS - CoV - 2 vaccines perform well in reducing severe cases, their effectiveness in preventing infection is not satisfactory. - Emerging variants such as JN.1 have stronger immune evasion capabilities, and there is an urgent need to develop a new - generation vaccine to deal with future infections and transmissions. - The ideal new - generation SARS - CoV - 2 vaccine should simultaneously address three key challenges: generate a high level of cross - protection, establish effective mucosal immunity, and make protective immunity long - lasting. ### Research methods: - **Animal experiments**: Intranasal vaccination with the 3R - NC + KFD vaccine was carried out in mice to evaluate the immune response and protection effect induced by it. - **Clinical trials**: An open - label clinical trial was carried out in people who had been vaccinated with inactivated SARS - CoV - 2 vaccine (IAV) to evaluate the safety and immunogenicity of the 3R - NC + KFD vaccine. ### Main findings: - **Long - lasting neutralizing antibody response**: The 3R - NC + KFD vaccine induced a high level of RBD - specific neutralizing antibodies in mice, and these antibodies could last up to 13 months in serum and mucosal sites. - **Effective mucosal immunity**: The 3R - NC + KFD vaccine successfully induced a long - lasting salivary and vaginal IgA response in mice. - **Ability to deal with new variants**: The updated triple RBD scaffold protein can induce an adaptive antibody response and neutralize emerging variants such as JN.1. - **Clinical safety**: Clinical trials in human volunteers showed that the 3R - NC + KFD vaccine has good safety and immunogenicity and significantly increases the level of neutralizing antibodies against SARS - CoV - 2 and its variants. ### Conclusion: The research results indicate that the 3R - NC + KFD vaccine is a potential mucosal vaccine prototype and can provide broad - spectrum protection against SARS - CoV - 2 and its variants.